secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001104659-24-062001
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Q1 net loss narrows to $2.4M; MT-601 shows durable CRs in APOLLO trial
-----------------------------------------------------------------------------

- Net loss of $2.4M in Q1 2024 vs $4.9M in Q1 2023; cash $11.3M expected to fund into Q4 2025.
- Three patients treated with MT-601: 2 complete responses (one >9 months after CAR-T relapse) and 1 partial response; well tolerated.
- MT-601 received nonproprietary name 'neldaleucel' from USAN/INN; more data expected H2 2024.
- MT-401-OTS IND cleared for AML/MDS; clinical initiation expected H2 2024; secured $2M NIH SBIR funding.
- R&D expenses $2.6M, G&A $1.2M, both down YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924062001/0001104659-24-062001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924062001/tm2414438d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-062001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer